Biosensors,
Год журнала:
2025,
Номер
15(2), С. 85 - 85
Опубликована: Фев. 4, 2025
Alzheimer’s
disease
(AD)
is
a
prevalent
neurodegenerative
disorder
and
significant
cause
of
dementia
in
elderly
individuals,
with
growing
prevalence
our
aging
population.
Extracellular
amyloid-β
peptides
(Aβ),
intracellular
tau
proteins,
their
phosphorylated
forms
have
gained
prominence
as
critical
biomarkers
for
early
precise
diagnosis
AD,
correlating
progression
response
to
therapy.
The
high
costs
invasiveness
conventional
diagnostic
methods,
such
positron
emission
tomography
(PET)
magnetic
resonance
imaging
(MRI),
limit
suitability
large-scale
or
routine
screening.
However,
electrochemical
(EC)
analysis
methods
made
progress
detection
due
sensitivity,
excellent
specificity,
portability,
cost-effectiveness.
This
article
reviews
the
EC
biosensing
technologies,
focusing
on
protein
blood
(a
low-invasive,
accessible
medium).
then
discusses
various
sensing
platforms,
including
fabrication
processes,
(LOD),
clinical
potential
show
role
these
sensors
transformers
changing
face
AD
diagnostics.
Cells,
Год журнала:
2022,
Номер
11(17), С. 2728 - 2728
Опубликована: Сен. 1, 2022
Alzheimer’s
disease
(AD)
is
the
most
common
form
of
dementia
worldwide,
with
a
complex,
poorly
understood
pathogenesis.
Cerebral
atrophy,
amyloid-β
(Aβ)
plaques,
and
neurofibrillary
tangles
represent
main
pathological
hallmarks
AD
brain.
Recently,
neuroinflammation
has
been
recognized
as
prominent
feature
brain
substantial
evidence
suggests
that
inflammatory
response
modulates
progression.
Additionally,
dysregulation
calcium
(Ca2+)
homeostasis
represents
another
early
factor
involved
in
pathogenesis,
intracellular
Ca2+
concentration
essential
to
ensure
proper
cellular
neuronal
functions.
Although
growing
supports
involvement
mechanisms
neurodegeneration-related
processes,
scant
data
are
available
on
its
contribution
microglia
astrocytes
functioning,
both
health
throughout
continuum.
Nevertheless,
AD-related
aberrant
signalling
crucially
underpinning
neuroinflammatory
processes
that,
turn,
impact
function.
In
this
light,
we
attempted
provide
an
overview
current
understanding
interactions
between
glia
cells-mediated
responses
molecular
AD.
Sensors,
Год журнала:
2023,
Номер
23(9), С. 4184 - 4184
Опубликована: Апрель 22, 2023
Alzheimer's
disease
(AD)
is
now
classified
as
a
silent
pandemic
due
to
concerning
current
statistics
and
future
predictions.
Despite
this,
no
effective
treatment
or
accurate
diagnosis
currently
exists.
The
negative
impacts
of
invasive
techniques
the
failure
clinical
trials
have
prompted
shift
in
research
towards
non-invasive
treatments.
In
light
there
growing
need
for
early
detection
AD
through
approaches.
abundance
data
generated
by
such
blood
component
monitoring,
imaging,
wearable
sensors,
bio-sensors
not
only
offers
platform
more
reliable
bio-marker
developments
but
also
significantly
reduces
patient
pain,
psychological
impact,
risk
complications,
cost.
Nevertheless,
are
challenges
computational
analysis
large
quantities
generated,
which
can
provide
crucial
information
AD.
Hence,
integration
artificial
intelligence
deep
learning
critical
addressing
these
challenges.
This
work
attempts
examine
some
facts
situation
approaches
leveraging
potential
tools
utilizing
vast
amount
order
revolutionize
according
principles
new
medicine
era.
Biomedicines,
Год журнала:
2023,
Номер
11(9), С. 2587 - 2587
Опубликована: Сен. 21, 2023
The
nuclear
factor
kappa
B
(NF-κB)
pathway
has
emerged
as
a
pivotal
player
in
the
pathogenesis
of
various
diseases,
including
neurodegenerative
illnesses
like
Alzheimer’s
disease
(AD).
involvement
NF-κB
immune
system
responses,
inflammation,
oxidative
stress,
and
neuronal
survival
highlights
its
significance
AD
progression.
We
discuss
advantages
inhibition,
potential
to
mitigate
neuroinflammation,
modulate
amyloid
beta
(Aβ)
production,
promote
survival.
However,
we
also
acknowledge
limitations
challenges
associated
with
this
approach.
Balancing
fine
line
between
dampening
inflammation
preserving
physiological
responses
is
critical
avoid
unintended
consequences.
This
review
combines
current
knowledge
on
pathway’s
intricate
pathogenesis,
emphasizing
therapeutic
target.
By
evaluating
both
limitations,
provide
holistic
view
feasibility
modulation
treatment.
As
quest
for
effective
therapies
continues,
an
in-depth
understanding
multifaceted
roles
will
guide
development
targeted
interventions
improve
management.
Frontiers in Neuroscience,
Год журнала:
2023,
Номер
17
Опубликована: Сен. 5, 2023
Neuropsychiatric
symptoms
(NPS)
in
Alzheimer's
disease
(AD)
affect
up
to
97%
of
AD
patients,
with
an
estimated
80%
current
patients
experiencing
these
symptoms.
Common
AD-associated
NPS
include
depression,
anxiety,
agitation,
aggression,
and
apathy.
The
severity
is
typically
linked
the
disease's
progression
extent
cognitive
decline.
Additionally,
are
responsible
for
a
significant
increase
morbidity,
mortality,
caregiver
burden,
earlier
nursing
home
placement,
greater
healthcare
expenditure.
Despite
their
high
prevalence
impact,
there
notable
lack
clinical
research
on
AD.
In
this
article,
we
explore
analyze
prevalence,
symptom
manifestations,
challenges
diagnosis,
treatment
options
associated
Our
literature
review
reveals
that
distinguishing
accurately
diagnosing
remains
challenging
task
settings.
It
often
difficult
discern
whether
secondary
pathophysiological
changes
from
or
comorbid
psychiatric
conditions.
Furthermore,
availability
effective
pharmaceutical
interventions,
as
well
non-pharmacotherapies
AD,
limited.
By
highlighting
advance
diagnosis
NPS,
aspire
offer
new
insights
into
complexity
identifying
treating
within
context
contribute
deeper
understanding
multifaceted
nature
Biomedicines,
Год журнала:
2025,
Номер
13(2), С. 279 - 279
Опубликована: Янв. 23, 2025
Alzheimer’s
disease
(AD)
is
traditionally
viewed
through
the
lens
of
amyloid
cascade
hypothesis,
implicating
amyloid-beta
and
tau
protein
aggregates
as
main
pathological
culprits.
However,
burgeoning
research
points
to
brain’s
resident
immune
cells,
microglia,
critical
players
in
AD
pathogenesis,
progression,
potential
therapeutic
interventions.
This
review
examines
dynamic
roles
microglia
within
intricate
framework
AD.
We
detail
involvement
these
cells
neuroinflammation,
explaining
how
their
activation
response
fluctuations
may
influence
trajectory.
further
elucidate
complex
relationship
between
pathology.
study
highlights
dual
nature
which
contribute
both
aggregation
clearance
protein.
Moreover,
an
in-depth
analysis
interplay
unveils
significant,
yet
often
overlooked,
impact
this
interaction
on
neurodegeneration
Shifting
from
conventional
approaches,
we
assess
current
treatments
primarily
targeting
introduce
novel
strategies
that
involve
manipulating
microglial
functions.
These
innovative
methods
herald
a
paradigm
shift
management
Finally,
explore
field
precision
diagnosis
pursuit
robust
biomarkers.
underline
more
profound
comprehension
biology
could
enrich
essential
areas,
potentially
paving
way
for
accurate
diagnostic
tools
tailored
treatment
strategies.
In
conclusion,
expands
perspective
pathology
treatment,
drawing
attention
multifaceted
microglia.
As
continue
enhance
our
understanding
microglial-focused
interventions
emerge
promising
frontier
bolster
arsenal
fight
against
Journal of Alzheimer s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 12, 2025
Background
Lecanemab,
a
novel
monoclonal
antibody
targeting
amyloid-β,
has
shown
promise
in
treating
Alzheimer's
disease.
Comprehensive
post-marketing
safety
data
analysis
is
crucial
to
understand
its
real-world
risk
profile.
Objective
This
study
aimed
evaluate
the
profile
of
lecanemab
using
from
FDA
Adverse
Event
Reporting
System
(FAERS),
with
focus
on
nervous
system
disorders
and
amyloid-related
imaging
abnormalities.
Methods
We
conducted
disproportionality
FAERS
database
signals
associated
lecanemab.
odds
ratio
(ROR),
proportional
reporting
ratio,
empirical
Bayesian
geometric
mean,
information
component
were
calculated
at
both
organ
class
(SOC)
preferred
term
(PT)
levels.
Additionally,
we
performed
time-to-onset
Weibull
shape
parameter
estimation.
Results
Analysis
SOC
level
revealed
significant
for
(ROR:
7.32,
95%
CI:
6.69–8.00).
At
PT
level,
strong
observed
abnormalities,
particularly
those
microhemorrhages
oedema
4122.81
3922.78,
respectively).
Headache
was
most
frequently
reported
adverse
event
(200
cases),
followed
by
chills
(107
cases)
fatigue
(97
cases).
Time-to-onset
showed
median
time
33
days
(range:
1–1283)
all
events,
neurological
events
occurring
slightly
later
(median:
42
days,
range:
1–1260).
Conclusions
Our
findings
highlight
distinct
lecanemab,
predominant
impact
notable
association
These
results
underscore
importance
vigilant
monitoring
further
research
optimize
risk-benefit
clinical
practice.
Journal of Translational Medicine,
Год журнала:
2025,
Номер
23(1)
Опубликована: Янв. 27, 2025
Alzheimer's
disease
(AD)
is
the
most
frequent
neurodegenerative
disorder
worldwide.
The
great
variability
in
evolution
and
incomplete
understanding
of
molecular
mechanisms
underlying
AD
make
it
difficult
to
predict
when
a
patient
will
convert
from
prodromal
stage
dementia.
We
hypothesize
that
metabolic
alterations
present
at
level
brain
could
be
reflected
systemic
blood
serum
patients,
these
used
as
prognostic
biomarkers.
This
pilot
study
proposes
investigation
via
nuclear
magnetic
resonance
(NMR)
spectroscopy
consecutive
series
patients
including
57
affected
by
dementia
(AD-dem)
45
with
mild
cognitive
impairment
(MCI)
due
(MCI-AD).
As
control
group,
we
considered
31
subjects
whom
other
disorders
were
excluded
(MCI).
A
panel
26
metabolites
112
lipoprotein-related
parameters
was
quantified
logistic
LASSO
regression
algorithm
employed
identify
optimal
combination
metabolites-lipoproteins
their
ratios
discriminate
groups
interest.
In
training
set,
our
model
classified
AD-dem
MCI
an
accuracy
81.7%.
These
results
reproduced
validation
set
(accuracy
75.0%).
Evolution
MCI-AD
evaluated
over
time.
Patients
who
displayed
decrease
MMSE
<
1.5
point
per
year
lower
progression
rate:
obtained
division
18
rate
(MCI-AD
LR)
27
higher
HR).
calculated
using
4
features
identified
LR
HR
73.3%.
identification
potential
novel
peripheral
biomarkers
disease,
proposed
this
study,
opens
new
prospect
for
innovative
minimally
invasive
method
its
very
early
stages.
approach
able
sub-stratify
identifying
those
associated
faster
clinical
progression.